YKL-40 levels in serum and plasma samples provide as an indicator of both the presence of early stage ovarian cancer and of its aggressiveness. Thus testing for YKL-40 levels in patients at risk but not yet displaying symptoms associated with ovarian cancer, or in patients newly diagnosed with early stage ovarian cancer (Stage I or II) enhance both the detection of early stage ovarian cancer and selection of treatment protocols used for early stage ovarian cancer patients.
申请公布号
WO2005039487(A2)
申请公布日期
2005.05.06
申请号
WO2004US29902
申请日期
2004.09.10
申请人
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH;SPRIGGS, DAVID;FLEISHER, MARTIN;TANWAR, MEENA;DUPONT, JAKOB
发明人
SPRIGGS, DAVID;FLEISHER, MARTIN;TANWAR, MEENA;DUPONT, JAKOB